Related content

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis

By Jönsson B.   Ström O.   Eisman J.   Papaioannou A.   Siris E.   Tosteson A.   Kanis J.  

Osteoporosis International, Vol. 22, Iss. 3, 2011-03 ,pp. : 967-982

Springer Publishing Company

Access to resources Recommend Favorite

Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women

By Ringe J. D.   Christodoulakos G. E.   Mellström D.   Petto H.   Nickelsen T.   Marín F.   Pavo I.  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2677-2687

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of the treatment and prevention of osteoporosis—a review of the literature and a reference model

By Zethraeus N.   Borgström F.   Ström O.   Kanis J.   Jönsson B.  

Osteoporosis International, Vol. 18, Iss. 1, 2007-01 ,pp. : 9-23

Springer Publishing Company

Access to resources Recommend Favorite

The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden

By Zethraeus N.   Ström O.   Borgström F.   Kanis J.   Jönsson B.  

Osteoporosis International, Vol. 19, Iss. 6, 2008-06 ,pp. : 819-827

Springer Publishing Company

Access to resources Recommend Favorite

Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates

By Earnshaw S. R.   Graham C. N.   Ettinger B.   Amonkar M. M.   Lynch N. O.   Middelhoven H.  

Current Medical Research and Opinion, Vol. 23, Iss. 10, 2007-10 ,pp. : 2517-2529

Informa Healthcare

Access to resources Recommend Favorite